BioMark Diagnostics

BioMark Diagnostics Debt

The Debt of BioMark Diagnostics (BUX.CN) as of Oct 16, 2026 is 160,710.00 CAD. In the previous year, Debt was 454,160.00 CAD — a change of -64.61% (lower).

Debt

160,710.00CAD

YoY

-64.61%

Last updated:

In 2025, BioMark Diagnostics's total debt was 160,710.00 CAD, a -64.61% change from the 454,160.00 CAD total debt recorded in the previous year.

The BioMark Diagnostics Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
0.00 CAD
Jan 1, 2019
0.00 CAD
Jan 1, 2020
0.00 CAD
Jan 1, 2021
109,620.00 CAD
Jan 1, 2022
750,080.00 CAD
Jan 1, 2023
446,470.00 CAD
Jan 1, 2024
454,160.00 CAD
Jan 1, 2025
160,710.00 CAD
The BioMark Diagnostics Debt history
YEARDebtYoY
160,710.00CAD-64.61%
454,160.00CAD+1.72%
446,470.00CAD-40.48%
750,080.00CAD+584.25%
109,620.00CAD—
0.00CAD—
0.00CAD—
0.00CAD—
0.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioMark Diagnostics Stock analysis

What does BioMark Diagnostics do? BioMark Diagnostics Inc is a company based in Richmond, British Columbia, Canada. It focuses on developing and commercializing cancer diagnostic solutions for detecting, monitoring, and assessing treatment for cancer. The company went public through an IPO on November 3, 2014. BioMark Diagnostics is developing a molecular diagnostics technology platform that uses metabolomics and machine learning algorithms. This platform aims to bring new cancer diagnostics to market and improve cancer prognosis by enabling the detection of carcinomas in pre-symptomatic stages. The technology also supports measuring treatment response and serial monitoring of cancer survivors. The company's diagnostics platform leverages Omics and machine learning, with a focus on cancers that are difficult to detect and treat. A key component of its technology is a liquid biopsy assay that detects Spermidine/spermine N-acetyltransferase 1 (SSAT1), an enzyme with elevated levels in various cancers. Additionally, BioMark Diagnostics has developed a high-powered liquid biopsy metabolic panel assay designed for early-stage lung cancer diagnosis. Clinical detection capabilities of this metabolic panel have been demonstrated, though specific details are not provided. The company's website is https://www.biomarkdiagnostics.com/ and it operates under the ticker symbol BUX.CN with ISIN CA09073K1084. Its sector and industry classifications are listed as N/A on the provided data. The company is headquartered in Richmond, British Columbia, Canada. BioMark Diagnostics is one of the most popular companies on Eulerpool.

Debt Details

Understanding BioMark Diagnostics's Debt Structure

BioMark Diagnostics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing BioMark Diagnostics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to BioMark Diagnostics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in BioMark Diagnostics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about BioMark Diagnostics stock

Debt of BioMark Diagnostics is 160,710.00 CAD in 2025.

Debt of BioMark Diagnostics changed from 454,160.00 CAD to 160,710.00 CAD, representing a -64.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt BioMark Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Debt's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's BioMark Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — BioMark Diagnostics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — BioMark Diagnostics